New MenaQ7 patents granted to NattoPharma in US, Israel and Australia

6b8015c8-ad96-4c8c-a133-ab76615dc355articleimage.jpg

08 Nov 2017 --- NattoPharma ASA has successfully secured patents in Israel, the US and Australia for its “nature-identical synthesis” creating MenaQ7 PharmaPure Vitamin K2 as MK-7, adding further to the company’s patent portfolio.

“These patents underline our position as the leader in the vitamin K2 market,” Kjetil Ramsøy, NattoPharma Chief Financial Officer, tells NutritionInsight. “Having the most clinically validated vitamin K2 as MK-7 available today, and the only all-trans nature-identical synthetic available that is free of cis-isomers, this will give our partners the validation they need to ensure they are serving their customers the best possible product.”

Global success with patents
NattoPharma details the company’s progress with patents:

  • Israel: On July 31, 2017, patent #238199 “Process for preparation of MK-7 type of Vitamin K2” was granted.
  • US: On August 28, 2017, Notice of Allowance for patent #14/435,260 “Process for preparation of MK-7 type vitamin K2” was issued.
  • Australia: On July 5, 2017, Notice of Acceptance (NoA) was issued for patent #2013330517 “process for preparation of MK-7 type of vitamin K2.” This NoA was published on July 20.

“This unique patented process results in the world’s only truly all-trans synthetic vitamin K2 as MK-7,” says William Sommer, NattoPharma’s Vice President of Global Development & Regulatory. “Our material is of the highest quality and superior to anything else on the market, so much so that it is currently being utilized in two studies sponsored by the traditional medical community.”

“These studies are evidence that the medical community recognizes the difference a vitamin can make for human health, and in selecting MenaQ7 PharmaPure, they want to use the purest, all-trans material for future further confirmation and discovery of health benefits,” he continues. “This technology also ensures supplement providers deliver the MK-7 with the health benefits consumers desire.”

Sommer adds that NattoPharma has made significant intellectual and monetary investments technologies in, and that the company is committed to actively monitor market developments to protect the company’s intellectual property rights throughout their lifespan.

“The approval of these patents represents another milestone for NattoPharma and our partners,” concludes Sommer. “This further strengthens NattoPharma’s global intellectual property rights platform and improves our competitive position within the food supplement market.”

“We see a very positive development in the interest in vitamin K2, which is also supported by our global growth over the last couple of years,” Ramsøy notes to NutritionInsight. “We expect this to continue in the coming years as the knowledge about the benefits of Vitamin K2 grows even more in the consumer market.”

There are also plans to obtain patents for MenaQ7 in further countries. “Patents are currently pending in a number of different jurisdictions, both for the synthetic production patent for PharmaPure, as well as for different health claims related to the use of vitamin K2 as a dietary supplement,” Ramsøy explains.

By Paul Creasy

To contact our editorial team please email us at editorial@cnsmedia.com

NattoPharma ASA

Collapse

As the leader in Vitamin K2 research & development, NattoPharma has not only created the Vitamin K2 category, but continues to drive it forward. Offering the best and first clinically validated and patented Vitamin K2 as MK-7 on the market, MenaQ7®, NattoPharma has sponsored the groundbreaking research that has confirmed K2’s essential role in bone and cardiovascular health, for old and young alike.

NattoPharma’s mission is to advance global health by creating and introducing to the market scientifically validated products and technologies that will deliver measurable health benefits and optimal health outcomes.

This mission is accomplished by:

• Addressing significant health concerns with branded, scientifically validated, proprietary products and technologies, leading with our flagship brand MenaQ7®;

• Leveraging all manner of technology to more effectively and efficiently deliver these products to our target markets;

• Solidifying ourselves as the experts in the science underlying our products and associated enabling technologies that allow us to effectively deliver them to the marketplace; and

• Developing and maintaining a deep customer and segment understanding of the benefits we deliver.

With 19+ published studies and even more underway, NattoPharma has an unparalleled patent portfolio related to relevant health benefits and market segments, creating extra values for its customers.  

MenaQ7® meets the growing demand for highly pure, stable K2 for supplemental and food use in any different format.

The most comprehensive Vitamin K2 ingredient portfolio meeting market needs:

MenaQ7® Natural MK-7: 96% pure all-trans MK-7 free of soy and other allergens.

MenaQ7® PharmaPure MK-7: The only all-trans nature-identical synthetic, winner of 2015   NutrAward for Best Functional Ingredient

MenaQ7® Natto MK-7: 96% active all-trans soy fermented MK-7

MenaQ7® Full Spectrum K2: The first and only K2 to deliver menaquinone isomers MK-6, 7, 8, and 9, free from soy and other allergens.

All material is available with CryoCap microencapsulation, ensuring stable menaquinone protection in any formulation.

The MenaQ7® brand is built upon 6 Pillars of Excellence, a platform delivering the most safe and efficacious Vitamin K2 on the market, creating opportunities for manufacturers and value for end users:

• Trusted Expertise

• Science Leader

• Superior Products

• Continuous Innovation

• Educational Marketing

• Cooperative Support

Visit website for more information: www.menaq7.com 

Related Articles

Nutrition & Health News

Weekly Digest: Arla expands fiber yogurt range, probiotics may reduce hay fever symptoms

25 May 2018 --- This week in nutrition news, Arla revealed a new addition to its fiber yogurt range, hoping to boost the UK's daily fiber intake. In research news, probiotic formulations were found to have positive effects on hay fever symptoms, while following a diet high in antioxidants may protect people from the adverse effects of pollution. Furthermore, researchers have made steps in understanding the link between a mothers nutrition during pregnancy and the child's growth, and a study undercovered that consumers are more likely to order unhealthy options when dining out amid louder, ambient music.

Nutrition & Health News

Avoid the snacks? To manage weight, timing of protein supplements matters

25 May 2018 --- Protein supplementation is finding its way into an ever-increasing range of formats, with on-the-go snacks and “bite-size” in particular seeing tremendous growth. However, new research by nutrition experts at Purdue University has shown that people looking to manage their weight with strength-training and protein supplements should consume their supplementation during a meal. 

Nutrition & Health News

DuPont's probiotic reach expands with Brazilian recognition of health claim

25 May 2018 --- DuPont Nutrition & Health Science has earned approval from the Brazilian Health Regulatory Agency (ANVISA) for its Bifidobacterium lactis HN019 probiotic strain. The regulatory green light marks the recognition of the science behind the strain and allows an on-pack health claim. Customers in Brazil can now bring new probiotic products and dietary supplements faster to market using the first DuPont probiotic to qualify for an approved health claim on the local market.

Nutrition & Health News

calocurb: 100 percent plant-based weight management product launched in US market

25 May 2018 --- New Zealand-based nutrition and e-commerce company calocurb has launched its 100 percent plant-based, non-GMO weight management supplement into the US market. The product is designed to curb cravings and reduce calorie intake by around 20 percent at meal or snack time.

Nutrition & Health News

Microbiome solutions: A key theme at Vitafoods Europe 2018

24 May 2018 --- Research into the microbiome – the aggregated microbial species in our body – is gaining increasing attention and investment. Although the term is often associated with digestive health, the body, in fact, contains multiple microbiome. This is currently spurring on research and innovation in areas as wide-ranging as women’s health, weight management, immunity and skin health. At Vitafoods Europe 2018, NutritionInsight spoke with suppliers about their efforts and innovations in the microbiome space, using pre or probiotics for gut health and beyond.

More Articles
URL : http://www.nutritioninsight.com:80/news/new-menaq7-patents-granted-to-nattopharma-in-us-israel-and-australia.html